These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22525343)

  • 1. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes.
    Hughes AD; Park C; March K; Coady E; Khir A; Chaturvedi N; Thom SA
    Int J Cardiol; 2013 Aug; 167(4):1329-32. PubMed ID: 22525343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study.
    Ordu S; Ozhan H; Alemdar R; Aydin M; Basar C; Caglar O; Yazici M; Yalcin S
    Acta Cardiol; 2010 Aug; 65(4):401-6. PubMed ID: 20821932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.
    Horio T; Suzuki M; Suzuki K; Takamisawa I; Hiuge A; Kamide K; Takiuchi S; Iwashima Y; Kihara S; Funahashi T; Yoshimasa Y; Kawano Y
    Am J Hypertens; 2005 Jul; 18(7):949-57. PubMed ID: 16053992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
    Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
    Wallace TM; Levy JC; Matthews DR
    Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients].
    Terui G; Goto T; Katsuta M; Aoki I
    J Cardiol; 2006 Nov; 48(5):263-7. PubMed ID: 17136821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
    Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
    Sridhar S; Walia R; Sachdeva N; Bhansali A
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):454-9. PubMed ID: 22816533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
    Clarke GD; Solis-Herrera C; Molina-Wilkins M; Martinez S; Merovci A; Cersosimo E; Chilton RJ; Iozzo P; Gastaldelli A; Abdul-Ghani M; DeFronzo RA
    Diabetes Care; 2017 Nov; 40(11):1530-1536. PubMed ID: 28847910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
    Kumarathurai P; Sajadieh A; Anholm C; Kristiansen OP; Haugaard SB; Nielsen OW
    Cardiovasc Diabetol; 2021 Jan; 20(1):12. PubMed ID: 33413428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients.
    Terui G; Goto T; Katsuta M; Aoki I; Ito H
    J Cardiol; 2009 Aug; 54(1):52-8. PubMed ID: 19632520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.